

WHAT IS CLAIMED:

1. A method of treating atherosclerosis, comprising administering a therapeutically effective amount of a cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.

2. The method of Claim 1 wherein the cysteinyl leukotriene 2 receptor antagonist is a dual cysteinyl leukotriene 1 receptor antagonist and cysteinyl leukotriene 2 receptor antagonist.

3. The method of Claim 1 wherein the cysteinyl leukotriene 2 receptor antagonist is a selective cysteinyl leukotriene 2 receptor antagonist.

4. The method of Claim 1, wherein the cysteinyl leukotriene 2 receptor antagonist is selected from the group consisting of:

3-((carboxyacetal)amino)phenylthio)-4-nonyl-oxobenzenehexanoic acid, and

(2S, 3S, 2'S,3'S)-3,3'-[({3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}methylene)bis(thio))]bis(2-methylbutanoic acid).

5. A method for preventing or reducing the risk of atherosclerotic plaque rupture comprising administering a prophylactically effective amount of a cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.

6. The method of Claim 5 wherein the cysteinyl leukotriene 2 receptor antagonist is a dual cysteinyl leukotriene 1 receptor antagonist and cysteinyl leukotriene 2 receptor antagonist.

7. The method of Claim 5 wherein the cysteinyl leukotriene 2 receptor antagonist is a selective cysteinyl leukotriene 2 receptor antagonist.

8. The method of Claim 5, wherein the cysteinyl leukotriene 2 receptor antagonist is selected from the group consisting of:

3-((carboxyacetal)amino)phenylthio)-4-nonyl-oxobenzenehexanoic acid, and

(2S, 3S, 2'S,3'S)-3,3'-[({3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}methylene)bis(thio))]bis(2-methylbutanoic acid).

9. A method of treating an aortic aneurysm, comprising administering a therapeutically effective amount of a cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.

10. The method of Claim 9 wherein the cysteinyl leukotriene 2 receptor antagonist is a dual
5 cysteinyl leukotriene 1 receptor antagonist and cysteinyl leukotriene 2 receptor antagonist.

11. The method of Claim 9 wherein the cysteinyl leukotriene 2 receptor antagonist is a selective cysteinyl leukotriene 2 receptor antagonist.

12. The method of Claim 9, wherein the cysteinyl leukotriene 2 receptor antagonist is selected from the group consisting of:
3-((carboxyacetal)amino)phenylthio)-4-nonyl-oxobenzenehexanoic acid, and
(2S, 3S, 2'S,3'S)-3,3'-[({3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}methylene)bis(thio)]bis(2-
methylbutanoic acid.

13. A method of treating pulmonary fibrosis, comprising administering a therapeutically effective amount of a cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.

14. The method of Claim 13 wherein the cysteinyl leukotriene 2 receptor antagonist is a dual
20 cysteinyl leukotriene 1 receptor antagonist and cysteinyl leukotriene 2 receptor antagonist.

15. The method of Claim 13 wherein the cysteinyl leukotriene 2 receptor antagonist is a selective cysteinyl leukotriene 2 receptor antagonist.

16. The method of Claim 13, wherein the cysteinyl leukotriene 2 receptor antagonist is selected from the group consisting of:
3-((carboxyacetal)amino)phenylthio)-4-nonyl-oxobenzenehexanoic acid, and
(2S, 3S, 2'S,3'S)-3,3'-[({3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}methylene)bis(thio)]bis(2-
methylbutanoic acid.

17. A method of treating cerebral edema, comprising administering a therapeutically effective amount of a cysteinyl leukotriene 2 receptor antagonist to a patient in need of such treatment.

18. The method of Claim 17 wherein the cysteinyl leukotriene 2 receptor antagonist is a dual cysteinyl leukotriene 1 receptor antagonist and cysteinyl leukotriene 2 receptor antagonist.

19. The method of Claim 17 wherein the cysteinyl leukotriene 2 receptor antagonist is a
5 selective cysteinyl leukotriene 2 receptor antagonist.

20. The method of Claim 17, wherein the cysteinyl leukotriene 2 receptor antagonist is selected from the group consisting of:

3-((carboxyacetal)amino)phenylthio)-4-nonyl-oxobenzenehexanoic acid, and
10 (2S, 3S, 2'S,3'S)-3,3'-[({3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl}methylene)bis(thio)]bis(2-methylbutanoic acid).